Last reviewed · How we verify
Non-allergic asthma
Approved treatments
- Cutivate · Teva Pharm
- Foradil · Novartis
Foradil works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing. - Flonase · GSK (GlaxoSmithKline)
- Singulair · Genuine Research Center, Egypt
- Nasonex · University of Alberta
- Flixotide · Mundipharma Research Limited
- Fluticason · Creighton University
- Elocon · Merck & Co.
Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body. - Serevent · Fundacio Privada Mon Clinic Barcelona
- Singulair · Merck & Co.
Leukotriene receptor antagonist (LTRA) that blocks CysLT1 receptors, reducing bronchoconstriction, mucus production, and airway inflammation. - MOMETASONE
12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Non-allergic asthma patent landscape — cliff calendar, originator estates, attackable patents
- Non-allergic asthma treatment landscape brief
- Non-allergic asthma treatment updates RSS
Frequently asked questions about Non-allergic asthma
What drugs treat Non-allergic asthma?
Tracked treatments include Cutivate, Foradil, Flonase, Singulair, Nasonex, Flixotide, Fluticason, Elocon.
What is the treatment for Non-allergic asthma?
Standard treatment for Non-allergic asthma includes Cutivate, Foradil, Flonase, Singulair, Nasonex. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Non-allergic asthma patent cliff · Non-allergic asthma CI report
- Treatment: Cutivate · Teva Pharm
- Treatment: Foradil · Novartis
- Treatment: Flonase · GSK (GlaxoSmithKline)
- Treatment: Singulair · Genuine Research Center, Egypt
- Treatment: Nasonex · University of Alberta
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing